Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma Meeting Abstract
| Authors: | Middleton, M. R.; Steven, N. M.; Evans, T. J.; Infante, J. R.; Sznol, M.; Mulatero, C.; Hamid, O.; Shoushtari, A. N.; Shingler, W.; Johnson, A.; Patel, S.; Parker, D.; Krige, D.; McAlpine, C.; Coughlin, C. M.; Hassan, N. J.; Jakobsen, B. K.; Corrie, P. |
| Abstract Title: | Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 146s |
| Language: | English |
| ACCESSION: | WOS:000404665404055 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.3016 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3016 -- Source: Wos |
